Could This Small-Cap Biotech Stock Make You Rich?
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
Aimmune Therapeutics
AIMT
AIMT
$14.06
$0.15
1.1%
Price as of August 12, 2020, 2:11 p.m. EDT
View Interactive AIMT Charts
Aimmune Therapeutics, Inc.
Interactive Chart
News & Analysis: Aimmune Therapeutics
Is Aimmune Therapeutics a Buy?
Is this battered biotech stock now a good deal for investors?
Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript
AIMT earnings call for the period ending June 30, 2020.
Got $2,000? Investing in These 3 Small-Cap Stocks Can Make You Rich
These under-the-radar names pack some huge growth potential.
Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?
Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?
Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
Aimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call Transcript
AIMT earnings call for the period ending March 31, 2020.
Is Aimmune Therapeutics a Buy?
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment.
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
